Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 0.40 |
| ▸ | HTR2B | P41595 | 6/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.34 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL297012 | 0.88 | HTR2C (0.45) | HTR2CHTR2BTP53HTR2ANOS3 | |
| Hydrochloric Acid SCHEMBL1456315 | 0.86 | HTR2C (0.44) | HTR2CHTR2BTP53NOS3NOS1 | |
| SCHEMBL1420634 | 0.86 | HTR2C (0.44) | HTR2CHTR2BTP53NOS3NOS1 | |
| Trifluoroacetic Acid SCHEMBL23849718 | 0.85 | F2 (0.35) | HTR2CHTR2BTP53PARP1FPR2 | |
| SCHEMBL19485613 | 0.84 | HTR2C (0.36) | HTR2CHTR2BTP53HTR2APARP1 | |
| Hydrochloric Acid SCHEMBL3450852 | 0.84 | HTR2C (0.43) | HTR2CHTR2BTP53NOS3NOS1 | |
| SCHEMBL2853069 | 0.84 | HTR2C (0.43) | HTR2CHTR2BTP53NOS3NOS1 | |
| SCHEMBL25408273 | 0.84 | NOS3 (0.46) | HTR2CHTR2BTP53HTR2AACVRL1 | |
| Hydrochloric Acid SCHEMBL21597931 | 0.83 | HTR2C (0.42) | HTR2CHTR2BTP53NOS3NOS1 | |
| Tert-Butyl Formate SCHEMBL27812018 | 0.82 | TDP1 (0.38) | HTR2CHTR2BTP53HTR2APARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024499-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-07-02 | — | — | US | disclosed |
| US-12024499-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-07-02 | — | — | US | disclosed |
| CN-115677772-B | Compound and composition for EGFR kinase inhibitor and application thereof | 浙江大学智能创新药物研究院 | 2023-08-18 | — | — | CN | disclosed |
| US-20230002354-A1 | MUSCARINIC AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2023-01-05 | — | — | US | disclosed |
| US-11254656-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-02-22 | — | — | US | disclosed |
| EP-3331529-B1 | MUSCARINIC AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2021-09-29 | — | — | EP | disclosed |
| CN-108025004-B | Muscarinic agonists | 赫普泰雅治疗有限公司 | 2021-07-09 | — | — | CN | disclosed |
| US-20200354339-A1 | MUSCARINIC AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2020-11-12 | — | — | US | disclosed |
| WO-2017021729-A1 | MUSCARINIC AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-02-09 | — | — | WO | disclosed |
| EP-2215090-B1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2015-03-04 | — | — | EP | disclosed |
| US-20110230464-A1 | PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | US | disclosed |
| US-20110021496-A1 | THIENOPYRIMIDINE DERIVATIVES AS P13K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-01-27 | — | — | US | disclosed |
| US-20110021496-A1 | THIENOPYRIMIDINE DERIVATIVES AS P13K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-01-27 | — | — | US | disclosed |
| US-20110021496-A1 | THIENOPYRIMIDINE DERIVATIVES AS P13K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-01-27 | — | — | US | disclosed |
| EP-2215090-A1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-08-11 | — | — | EP | disclosed |
| EP-2205610-A1 | THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS | F. Hoffmann-Roche AG (CH) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009053715-A1 | THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009053715-A1 | THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009053716-A1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009053716-A1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230464-A1 | PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS | PIK3CA, PIK3CD, PI4KA | HTR2C 2618/4885HTR2B 2106/4885TP53 889/4885 |
| US-20200354339-A1 | MUSCARINIC AGONISTS | CHRM1, CHRM2, CHRM3 | HTR2C 697/4885HTR2B 621/4885TP53 2034/4885 |
| US-20110021496-A1 | THIENOPYRIMIDINE DERIVATIVES AS P13K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | HTR2C 2679/4885HTR2B 2046/4885TP53 351/4885 |
| US-20230002354-A1 | MUSCARINIC AGONISTS | CHRM1, CHRM2, CHRM3 | HTR2C 697/4885HTR2B 621/4885TP53 2034/4885 |
| US-11254656-B2 | Muscarinic agonists | CHRM1, CHRM2, CHRM3 | HTR2C 697/4885HTR2B 621/4885TP53 2034/4885 |
| US-12024499-B2 | Muscarinic agonists | CHRM1, CHRM2, CHRM3 | HTR2C 697/4885HTR2B 621/4885TP53 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.